Document is current
Any future updates will be listed below
-
Authors
Lit, Kwok Keung
Li, Cheuk Kwan Owen
Zhirenova, Zhamilya
Blocki, Anna
-
Funding
Funding for this research was provided by:
University Grants Committee (GRF (14115723))
Health@InnoHK program launched by Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region of the People’s Republic of China (Center for Neuromusculoskeletal Restorative Medicine (CNRM))
Health and Medical Research Fund (08191066)
Faculty of Medicine, Chinese University of Hong Kong (4054732)
Innovation and Technology Commission (ITS/173/20)
- License Information
-
More Information
Article History
Received: 3 September 2025
Accepted: 19 November 2025
First Online: 2 December 2025
Declarations
:
: All primary human cells used in this study were purchased from commercial vendors, who had obtained the initial ethical approval and donors’ signed informed consent for the collection of cells. Material transfer agreement are available on Millipore ( ) and ATCC ( ) website. All animal experiment procedures were approved by the Animal Experimentation Ethics Committee, The Chinese University of Hong Kong, entitled “Pro-reparative extracellular matrix composite for resolution of chronic wounds in non-diabetic and diabetic mice” (Ref. No. 22-290-MIS) on 3rd Febuary 2023. The work has been reported in line with the ARRIVE guidelines 2.0.
: KKL and AB have filed a provisional US patent application relevant to the here disclosed content. Other than that authors declare no conflict of interest.
